Astellas Grows Oncology Portfolio With Ganymed Purchase

Astellas Pharma has acquired Ganymed Pharmaceuticals for an upfront cost of €422m to get access to the German firm's cancer antibody pipeline.

To further increase its oncology portfolio, highlighted as one of its core therapy areas and a key driver in its long term sustainable growth, Astellas Pharma Inc. has acquired Ganymed Pharmaceuticals AG, a German biopharma focused on developing immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMAbs).

In its 3Q earnings call on Oct. 28, the big pharma said that Ganymed was a fitting addition to its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip